
SWTX
SpringWorks Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
2.78B
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
74.09M
EV
3.25B
EV/OCF(TTM)
--
P/S(TTM)
15.92
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
86.45M
+75.35%
-1.120
+7.69%
73.39M
+22.86%
-1.050
+45.83%
66.95M
+218.74%
-0.970
+79.63%
Estimates Revision
The market is revising Downward the revenue expectations for SpringWorks Therapeutics, Inc. (SWTX) for FY2025, with the revenue forecasts being adjusted by -2.03% over the past three months. During the same period, the stock price has changed by 1.75%.
Revenue Estimates for FY2025
Revise Downward

-2.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+13.77%
In Past 3 Month
Stock Price
Go Up

+1.75%
In Past 3 Month
6 Analyst Rating

Wall Street analysts forecast SWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SWTX is 53.17 USD with a low forecast of 47.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
5 Hold
0 Sell
Hold

Current: 0

Low
47.00
Averages
53.17
High
84.00

Current: 0

Low
47.00
Averages
53.17
High
84.00
BofA
NULL -> No Rating
downgrade
$47
2025-04-25
Reason
BofA
Price Target
$47
2025-04-25
downgrade
NULL -> No Rating
Reason
BofA is moving to No Rating on SpringWorks Therapeutics (SWTX) given that shares are trading near the Merck KGaA (MKGAY) potential offer price of $47 per share and "no longer trading on fundamentals." A $47 per share price, while below expectations, would be a validation of the market opportunity for Gomekli and Ogsiveo, the analyst stated.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-24
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$74
2025-02-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-21
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$74
2025-02-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-12
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$74
2025-02-12
Reiterates
Strong Buy
Reason
Evercore ISI Group
Cory Kasimov
Buy
Maintains
$60 → $65
2025-02-12
Reason
Evercore ISI Group
Cory Kasimov
Price Target
$60 → $65
2025-02-12
Maintains
Buy
Reason
Wedbush
David Nierengarten
Buy
Reiterates
$77
2025-02-12
Reason
Wedbush
David Nierengarten
Price Target
$77
2025-02-12
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for SpringWorks Therapeutics Inc (SWTX.O) is -13.72, compared to its 5-year average forward P/E of -15.93. For a more detailed relative valuation and DCF analysis to assess SpringWorks Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-15.93
Current PE
-13.72
Overvalued PE
-5.92
Undervalued PE
-25.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-11.90
Current EV/EBITDA
-26.02
Overvalued EV/EBITDA
-3.59
Undervalued EV/EBITDA
-20.21
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
465.91
Current PS
9.27
Overvalued PS
1426.93
Undervalued PS
-495.11
Financials
Annual
Quarterly
FY2025Q1
YoY :
+133.68%
49.09M
Total Revenue
FY2025Q1
YoY :
-14.26%
-80.54M
Operating Profit
FY2025Q1
YoY :
-4.80%
-83.19M
Net Income after Tax
FY2025Q1
YoY :
-5.93%
-1.11
EPS - Diluted
FY2025Q1
YoY :
-13.48%
-68.79M
Free Cash Flow
FY2025Q1
YoY :
-1.56%
92.81
Gross Profit Margin - %
FY2025Q1
YoY :
-59.26%
-169.47
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
25.1M
USD
12
6-9
Months
2.9M
USD
2
0-12
Months
2.8M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
243.8K
Volume
1
6-9
Months
383.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
981.8K
Volume
Months
6-9
5
5.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
25.1M
USD
12
6-9
Months
2.9M
USD
2
0-12
Months
2.8M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SWTX News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
08:30:11
Sixteen option delistings on July 22nd

2025-07-18 (ET)
2025-07-18
11:34:22
SpringWorks reports conditional approval of Ezmekly in EU

2025-05-23 (ET)
2025-05-23
08:01:18
SpringWorks Therapeutics receives positive CHMP opinion for mirdametinib

Sign Up For More Events
Sign Up For More Events
News
9.0
06-20NewsfilterSpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
3.0
06-16NASDAQ.COMValidea Detailed Fundamental Analysis - SWTX
7.0
06-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Sign Up For More News
People Also Watch

IREN
IREN Ltd
17.720
USD
-2.32%

ODD
Oddity Tech Ltd
67.890
USD
-2.22%

MRCY
Mercury Systems Inc
52.980
USD
+0.99%

AIN
Albany International Corp
72.230
USD
+0.58%

KLIC
Kulicke and Soffa Industries Inc
34.000
USD
-0.73%

CSAN
Cosan SA
4.320
USD
+1.65%

BANC
Banc of California Inc
15.110
USD
+3.56%

SGRY
Surgery Partners Inc
21.260
USD
+1.19%

AMRX
Amneal Pharmaceuticals Inc
8.060
USD
+0.75%

RXRX
Recursion Pharmaceuticals Inc
6.490
USD
+3.67%
FAQ

What is SpringWorks Therapeutics Inc (SWTX) stock price today?
The current price of SWTX is 0 USD — it has increased 0.02 % in the last trading day.

What is SpringWorks Therapeutics Inc (SWTX)'s business?

What is the price predicton of SWTX Stock?

What is SpringWorks Therapeutics Inc (SWTX)'s revenue for the last quarter?

What is SpringWorks Therapeutics Inc (SWTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for SpringWorks Therapeutics Inc (SWTX)'s fundamentals?

How many employees does SpringWorks Therapeutics Inc (SWTX). have?
